Author

Matthew Gumbleton

University of UtahORCID 0000-0003-4882-4116Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Aria VaishnaviiD· 1 shared Benjamin T. SpikeiD· 1 shared Brandon MurphyiD· 1 shared Conan Grant KinseyiD· 1 shared Eric L. SnyderiD· 1 shared Headtlove Essel DadzieiD· 1 shared Jing WangiD· 1 shared John Victor HeymachiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aria VaishnaviORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 6, 2025

HNF4α controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung

Headtlove Essel Dadzie, Yangsook Song Green, Soledad A. Camolotto…·Eric L. Snyder

DOI 10.1101/2025.06.06.658155

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 4, 2025

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

Mélanie A. Dacheux, Mengting Wu, Michael T. Scherzer…·Aria Vaishnavi

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

DOI 10.1101/2025.05.04.652129

humanproteomics

𝕏 PostBluesky